Clinical Trials
12 trialsNCT07205315 2026-05-27
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
Grit Biotechnology
Phase EARLY_PHASE1 Recruiting
NCT06662227 2026-05-07
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
Phase EARLY_PHASE1 Suspended
NCT07376642 2026-03-30
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd
Phase EARLY_PHASE1 Recruiting
NCT06446128 2025-08-21
A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)
Shanghai Cell Therapy Group Co.,Ltd
Phase EARLY_PHASE1 Recruiting
NCT07048353 2025-07-02
CAR-T，MTD
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Phase EARLY_PHASE1 Not yet recruiting
NCT04191941 2019-12-10
Treatment of Hematological Malignancy With Novel CAR-T Cells.
Timmune Biotech Inc.
Phase EARLY_PHASE1 Unknown
NCT04156178 2019-11-12
CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT04156243 2019-11-12
CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies
iCell Gene Therapeutics
Phase EARLY_PHASE1 Unknown
NCT03690310 2019-01-31
Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03824951 2019-01-31
Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03824964 2019-01-31
Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT03692767 2019-01-30
Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
Allife Medical Science and Technology Co., Ltd.
Phase EARLY_PHASE1 Unknown